Phase II Trial of Adding UFUR to Non-small-cell Lung Cancer Patients Treated With Iressa
Iressa is a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).
It is an orally active agent for advanced non-small-cell lung cancer (NSCLC) in those who
have failed a previous platinum-based regimen and taxane treatment. UFUR (Tegafur/Uracil) is
effective agent against chemo-naïve NSCLC. It has anti-angiogenesis effect when used as
long-term low dose treatment.
Present phase II randomized clinical trial is designed to answer whether or not adding an
oral anti-angiogenesis agent (UFUR), that has low toxicity profiles when long term use, to
EGFR-TKI (Iressa) could increase patients survival and response rate.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess and compared the 6-month survival rate of these two arms of treatment.
Yuh-Min Chen, MD, PhD.
Chest Department, Taipei VGH
Taiwan: Department of Health